Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Mineralys Therapeutics, Inc. reported quarter and fiscal year ended December 31, 2023 results: net income Net loss was $71.9 million for the year ended December 31, 2023, compared to $29.8 million for the year ended December 3.
- Period
- quarter and fiscal year ended December 31, 2023
- Net income
- Net loss was $71.9 million for the year ended December 31, 2023, compared to $29.8 million for the year ended December 3
- Result
- reported results
Exact text from the filing
Net loss was $71.9 million for the year ended December 31, 2023, compared to $29.8 million for the year ended December 31, 2022.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Mineralys Therapeutics, Inc. entered into ATM Equity Offering Sales Agreement with BofA Securities, Inc. and Evercore Group L.L.C. valued at $100,000,000 (effective 2024-03-21).
- Action
- entry
- Agreement
- atm program
- Counterparty
- BofA Securities, Inc. and Evercore Group L.L.C.
- Value
- $100,000,000
- Effective
- 2024-03-21
Exact text from the filing
On March 21, 2024, Mineralys Therapeutics, Inc. (the “Company”), entered into an ATM Equity Offering Sales Agreement (the “Agreement”) with BofA Securities, Inc. and Evercore Group L.L.C. as the Company’s sales agents (the “Agents”) and/or principals. Pursuant to the terms of the Agreement, the Company may sell from time to time through the Agents shares of the Company’s common stock having an aggregate offering price of up to $100,000,000 (the “Shares”).
View on SEC.gov